Dose-dependent inhibition of thyroid differentiation by RAS oncogenes

Area of Science:

• Molecular Biology
• Oncology
• Endocrinology

Background:

• Activating RAS protooncogene mutations are linked to various thyroid cancers, including aggressive anaplastic thyroid carcinoma.
• RAS oncogene expression in thyroid cells mimics the loss of differentiated phenotype observed in anaplastic thyroid carcinoma.

Purpose of the Study:

• To investigate the dose-dependent effects of RAS oncogenes on thyroid epithelial cell differentiation.
• To determine the timing of RAS-induced changes in thyroid cell differentiation and growth.

Main Methods:

• Established FRTL-5 rat thyroid cell lines stably expressing constitutively active RAS (viral or cellular) and a tamoxifen-inducible RAS oncoprotein.
• Utilized real-time PCR to measure thyroid-specific gene expression in RAS-transformed cells.
• Assessed TSH-independent growth and the activity of transcription factors Titf1 and Pax8.

Main Results:

• A clear loss of thyroid cell differentiation was observed only with high RAS oncogene expression.
• TSH-independent growth was induced by both low and high levels of oncogenic RAS.
• Inhibition of differentiation is an early RAS-induced phenomenon, with high RAS doses affecting Titf1 and Pax8 activity.

Conclusions:

• RAS oncogenes exhibit a dose-dependent effect on thyroid epithelial differentiation.
• High levels of RAS oncogenes inhibit differentiation by targeting transcription factors like Titf1 and Pax8.
• RAS-induced inhibition of differentiation is an early event in thyroid cancer progression.